Previous 10 | Next 10 |
The Centers for Disease Control and Prevention (CDC) on Thursday revised recommendations for unvaccinated people easing the guidance on isolation following exposure to the virus. Per the latest advice, the CDC no longer recommends unvaccinated people to quarantine after exposure, ...
Regeneron's ( NASDAQ: REGN ) oral IPR hearing on the IPR on ‘338 MOU patent on Wednesday suggests that the company could lose the patent, according to Jefferies. "We went into trial believing that REGN could lose the IPR on ‘338 MOU patent – the oral h...
The clinical-stage biotech Kodiak Sciences ( NASDAQ: KOD ) jumped ~15% in the morning hours Monday after the company said its BEACON Phase 3 study for lead asset tedromer met the primary endpoint in patients with macular edema due to retinal vein occlusion. The global trial invo...
A major piece of legislation approved in the Senate on Sunday did not include a provision that would have capped the monthly cost for insulin to $35 in private insurance plans. The Inflation Reduction Act, passed along party lines, does cement a $35 maximum monthly cost for those ...
Teva Pharmaceutical's revenue was $3,786 million in Q2 2022, up 3.4% QoQ. The company's total debt continues to decline quarter on quarter and stands at $22,453 million at the end of Q2 2022. Teva Pharmaceutical has made progress in resolving opioid crisis lawsuits, reaching an ag...
Regeneron Pharmaceuticals (NASDAQ: REGN) has been a reliable, steadily growing stock over the years, with the top line and profits increasing. The company is coming off a fantastic 2021 as its COVID-19 treatment helped sales reach a record $16 billion -- nearly double the prior year...
Regeneron has just released its Q2 2022 earnings - revenues decreased by 44% year-on-year, to $2.86bn, but increased by 20% ex-REGEN-COV revenues. REGEN-COV - a COVID antiviral cocktail - made $5.8bn sales for Regeneron last year but is not effective against Omicron and will likely no...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biopharmaceutical companies have been struggling since 2021 and that narrative isn’t immediately changing. However, not every firm deserves this fate. In fact, investors can find great opportunities with “chea...
Moderna ( MRNA ), CVS Health ( CVS ), and Regeneron ( REGN ) dominated the top five intraday gainers in the S&P 500 on Wednesday after all three companies reported better than expected financials for 2Q 2022 before the market opened. Recording the sharpest intraday g...
Regeneron Pharmaceuticals, Inc. (REGN) Q2 2022 Earnings Conference Call August 03, 2022, 08:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Leonard Schleifer - President, Chief Executive Officer George Yancopoulos - President, Chief ...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...